

**POLICY:** Enzyme Replacement Therapy – Vimizim Utilization Management Medical Policy

- Vimizim® (elosulfase alfa intravenous infusion – BioMarin)

**EFFECTIVE DATE:** 1/1/2020**LAST REVISION DATE:** 04/16/2025**COVERAGE CRITERIA FOR:** All UCare Plans

---

**OVERVIEW**

Vimizim, a human *N*-acetylgalactosamine-6-sulfatase, is indicated for **Mucopolysaccharidosis type IVA** (Morquio A syndrome [MPS IVA]).<sup>1</sup> It is produced in Chinese hamster ovary cells via recombinant DNA technology. Vimizim is a hydrolytic lysosomal enzyme which is taken up by lysosomes and hydrolyzes sulfate from the non-reduced ends of the glycosaminoglycans keratan sulfate and chondroitin-6-sulfate.

**Disease Overview**

MPS IVA (Morquio A syndrome) is a rare lysosomal storage disorder characterized by deficient *N*-acetylgalactosamine-6-sulfatase activity leading to the accumulation of chondroitin-6-sulfate and keratan sulfate in lysosomes in bone, cartilage, and ligaments.<sup>2,3</sup> The clinical course, onset, and severity of MPS IVA is heterogeneous.<sup>2</sup> Manifestations of MPS IVA include short trunk dwarfism with short neck, kyphoscoliosis, odontoid dysplasia, knock-knee, cervical spinal cord compression, hypermobile joints, cardiac disease, respiratory insufficiency, obstructive sleep apnea, corneal clouding, and dental abnormalities.<sup>2-4</sup> MPS IVA has not been associated with cognitive decline.<sup>2</sup> The definitive diagnosis of MPS IVA is established by demonstrating deficient *N*-acetylgalactosamine-6-sulfatase activity in leukocytes or fibroblasts; or by genetic testing.<sup>2</sup> Definitive treatment for MPS IVA consists of enzyme replacement therapy with Vimizim. Hematopoietic stem cell transplantation is not recommended for MPS IVA.

**POLICY STATEMENT**

Prior Authorization is recommended for medical benefit coverage of Vimizim. Approval is recommended for those who meet the **Criteria** and **Dosing** for the listed indication. Extended approvals are allowed if the patient continues to meet the Criteria and Dosing. Requests for doses outside of the established dosing documented in this policy will be considered on a case-by-case basis by a clinician (i.e., Medical Director or Pharmacist). All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of patients treated with Vimizim as well as the monitoring required for adverse events and long-term efficacy, approval requires Vimizim to be prescribed by or in consultation with a physician who specializes in the condition being treated.

**Automation:** None.

## RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Vimizim is recommended in those who meet the following criteria:

### FDA-Approved Indication

- 1. Mucopolysaccharidosis Type IVA (Morquio A Syndrome).** Approve for 1 year if the patient meets BOTH of the following (A and B):
  - A)** The diagnosis is established by ONE of the following (i or ii):
    - i.** Patient has a laboratory test demonstrating deficient *N*-acetylgalactosamine-6-sulfatase activity in leukocytes or fibroblasts; OR
    - ii.** Patient has a molecular genetic test demonstrating biallelic pathogenic or likely pathogenic *N*-acetylgalactosamine-6-sulfatase (*GALNS*) gene variants; AND
  - B)** Vimizim is prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders.

**Dosing.** Approve up to 2 mg/kg of body weight administered intravenously no more frequently than once a week.

### CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Vimizim is not recommended in the following situations:

- 1.** Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

## REFERENCES

1. Vimizim® intravenous infusion [prescribing information]. Novato, CA: BioMarin; December 2019.
2. Akyol MU, et al. MPS Consensus Programme Co-Chairs. Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance. *Orphanet J Rare Dis.* 2019 Jun 13;14(1):137.
3. Tomatsu S, Yasuda E, Patel P, et al. Morquio A syndrome: Diagnosis and current and future therapies. *Pediatr Endocrinol Rev.* 2014;12:141-151.
4. Regier DS, Tanpaiboon P. Role of elosulfase alfa in mucopolysaccharidosis IVA. *Appl Clin Genet.* 2016;9:67-74.

## HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	No criteria changes.	04/12/2023
Annual Revision	<b>Mucopolysaccharidosis Type IVA (Morquio A Syndrome):</b> Confirmation of a genetic mutation in the <i>N</i> -acetylgalactosamine-6-sulfatase gene was revised to more specifically state, “genetic testing demonstrating biallelic pathogenic or likely pathogenic <i>N</i> -acetylgalactosamine-6-sulfatase gene variants”.	04/24/2024
UCare P&T Review	Policy reviewed and approved by UCare P&T committee. Annual review process	09/16/2024
Annual Revision	No criteria changes.	04/16/2025